Sarepta Therapeutics (SRPT)
$123.60
1.22 (0.98%)
SRPT Stock Quote Delayed 30 Minutes
Why Is Sarepta (SRPT) Stock Up 29% Today?
Sarepta (SRPT) stock is on the move Monday as investors react to FDA advisors voting on its gene therapy for Duchenne muscular dystrophy.
11 Best Stocks to Buy for 2023
INSIDE: Investing legend Louis Navellier reveals his Top 11 Stocks for 2023 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
11.51B
PE Ratio
-9.74
EPS
-12.69
Volume (Avg. Vol.)
1.03M
Day's Range
$122.93 - $125.92
52-Week Range
$61.28 - $159.89
Dividend & Yield
N/A (N/A)
SRPT Stock Predictions, Articles, and Sarepta Therapeutics News
Why Is Sarepta Therapeutics (SRPT) Stock Up 21% Today?
Sarepta Therapeutics (SRPT) stock is heading higher on Wednesday following the release of its latest earnings report and an upgrade.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!
Sarepta (SRPT) Stock Gains on FDA News
Sarepta Therapeutics (SRPT) stock is rising higher on Friday thanks to an update concerning its Duchenne muscular dystrophy treatment.
Positive Spin Isn’t Working for Sarepta Therapeutics
SRPT stock has some positives going for it but its underlying gene therapy solutions have questions that investors can’t shake.
SRPT Stock Alert: Why Sarepta Therapeutics Stock Is Plunging Today
Shares of SRPT stock are getting hammered on Friday after Sarepta Therapeutics reported negative results from a treatment trial.
Sarepta Therapeutics News: SRPT Stock Skyrockets 36% on FDA Approval of Muscular Dystrophy Drug
Sarepta Therapeutics (SRPT) has good news for SRPT stock investors concerning its treatment for Duchenne muscular dystrophy.
5 Top Stock Trades for Tuesday: AAPL, GM, SRPT
Apple, General Motors, Delta Air Lines, Sarepta and Bristol-Myers Squibb were our top stock trades to watch for Tuesday. Here's what you need to know.
Stock Market Today: Beyond Meat Makes a Friend on Wall Street
Apple's health initiative can't keep key people and Sarepta Therapeutics' CLR are a couple more top news items about the stock market today.
Nasdaq Today: Apple Loses Ive and the Nasdaq’s Q3 Outlook
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
5 Top Stock Trades for Monday: STZ, C, UBER
STZ beat on earnings, and the Fed approved higher dividends and buybacks for the bank stocks. Here are the top stock trades heading into next week.
7 Stocks to Buy for Over 20% Upside Potential
If you’re looking for a quick portfolio boost, look no further. Here are 7 stocks to buy with tons of upside according to top analysts.
Why Sarepta Therapeutics (SRPT) Stock Is Sinking Today
Sarepta Therapeutics (SRPT) stock is sinking after the company's late Tuesday announcement that it was offering a $350 million stock ofering.
Why NOW Is the Time to Buy Gene Therapy Stocks
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
Why Sarepta Therapeutics Stock Is Starting to Shine Again
SRPT stock rebounded nicely from its sub-$100 low last month. More upside is possible as the Sarepta ramps up an important study.
